Exagen Inc. (NASDAQ: XGN) is -54.72% lower on its value in year-to-date trading and has touched a low of $10.29 and a high of $29.86 in the current 52-week trading range. The XGN stock was last observed hovering at around $11.00 in the last trading session, with the day’s gains setting it 0.5%.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $11.50, the stock is -6.34% and -14.97% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 25307.0 and changing 4.55% at the moment leaves the stock -32.60% off its SMA200. XGN registered a loss of -55.32% in past 6-months. The firm has a 50-day simple moving average (SMA 50) of $12.71 and a 200-day simple moving average (SMA200) of $17.33.
The stock witnessed a -0.78% gain in the last 1 month and extending the period to 3 months gives it a -20.30%, and is -6.81% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.59% over the week and 8.33% over the month.
Exagen Inc. (XGN) has around 82 employees, a market worth around $154.56M and $40.70M in sales. Distance from 52-week low is 11.76% and -61.48% from its 52-week high. The company has generated returns on investments over the last 12 months (-11.40%).
Exagen Inc. (XGN) Analyst Forecasts
Exagen Inc. quarterly earnings per share for the current quarter are estimated at -$0.77 with sales reaching $4.47M over the same period.The EPS is expected to shrink by -430.00% this year, but quarterly earnings will post -18.90% year-over-year.
Exagen Inc. (XGN) Top Institutional Holders
59 institutions hold shares in Exagen Inc. (XGN), with 4.3M shares held by insiders accounting for 34.02% while institutional investors hold 87.60% of the company’s shares. The shares outstanding are 12.60M, and float is at 5.19M with Short Float at 2.16%. Institutions hold 57.80% of the Float.
The top institutional shareholder in the company is RTW Investments LP with over 1.26 million shares valued at $20.01 million. The investor’s holdings represent 9.94% of the XGN Shares outstanding. As of Mar 30, 2020, the second largest holder is Wasatch Advisors Inc with 0.69 million shares valued at $11.04 million to account for 5.48% of the shares outstanding. The other top investors are Victory Capital Management Inc. which holds 0.38 million shares representing 3.00% and valued at over $6.04 million, while Vanguard Group, Inc. (The) holds 2.22% of the shares totaling 0.28 million with a market value of $4.48 million.
Exagen Inc. (XGN) Insider Activity
A total of 15 insider transactions have happened at Exagen Inc. (XGN) in the last six months, with sales accounting for 11 and purchases happening 4 times. The most recent transaction is an insider sale by TULLIS JAMES L L, the company’s Director. SEC filings show that TULLIS JAMES L L sold 6,304 shares of the company’s common stock on Jun 09 at a price of $12.88 per share for a total of $81175.0. Following the sale, the insider now owns 1.61 million shares.
Exagen Inc. disclosed in a document filed with the SEC on Jun 09 that TULLIS JAMES L L (Director) sold a total of 578 shares of the company’s common stock. The trade occurred on Jun 09 and was made at $12.77 per share for $7383.0. Following the transaction, the insider now directly holds 40143.0 shares of the XGN stock.
Still, SEC filings show that on May 28, TULLIS JAMES L L (Director) disposed off 2,240 shares at an average price of $11.93 for $26724.0. The insider now directly holds 1,620,168 shares of Exagen Inc. (XGN).